These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 17761947)

  • 1. Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC).
    Kim DW; Chung HK; Park KC; Hwang JH; Jo YS; Chung J; Kalvakolanu DV; Resta N; Shong M
    Mol Endocrinol; 2007 Dec; 21(12):3039-49. PubMed ID: 17761947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation.
    Hwang JH; Kim DW; Suh JM; Kim H; Song JH; Hwang ES; Park KC; Chung HK; Kim JM; Lee TH; Yu DY; Shong M
    Mol Endocrinol; 2003 Jun; 17(6):1155-66. PubMed ID: 12637586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases.
    Hwang ES; Kim DW; Hwang JH; Jung HS; Suh JM; Park YJ; Chung HK; Song JH; Park KC; Park SH; Yun HJ; Kim JM; Shong M
    Mol Endocrinol; 2004 Nov; 18(11):2672-84. PubMed ID: 15297606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC.
    Kim YR; Byun HS; Won M; Park KA; Kim JM; Choi BL; Lee H; Hong JH; Park J; Seok JH; Kim DW; Shong M; Park SK; Hur GM
    BMC Cancer; 2008 May; 8():144. PubMed ID: 18498667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of LKB1 suppresses Stat3 activity to promote the proliferation of esophageal carcinoma cells.
    Wang YQ; Dai WM; Chu XY; Yang B; Zhao M; Sun Y
    Mol Med Rep; 2014 Jun; 9(6):2400-4. PubMed ID: 24676538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.
    Kim DW; Jo YS; Jung HS; Chung HK; Song JH; Park KC; Park SH; Hwang JH; Rha SY; Kweon GR; Lee SJ; Jo KW; Shong M
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4070-6. PubMed ID: 16849418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.
    Lodyga M; De Falco V; Bai XH; Kapus A; Melillo RM; Santoro M; Liu M
    Oncogene; 2009 Feb; 28(7):937-49. PubMed ID: 19060924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases.
    Jung HS; Kim DW; Jo YS; Chung HK; Song JH; Park JS; Park KC; Park SH; Hwang JH; Jo KW; Shong M
    Mol Endocrinol; 2005 Nov; 19(11):2748-59. PubMed ID: 15994200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase.
    De Falco V; Castellone MD; De Vita G; Cirafici AM; Hershman JM; Guerrero C; Fusco A; Melillo RM; Santoro M
    Cancer Res; 2007 Jan; 67(1):381-90. PubMed ID: 17210721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
    Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
    Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells.
    Castellone MD; Celetti A; Guarino V; Cirafici AM; Basolo F; Giannini R; Medico E; Kruhoffer M; Orntoft TF; Curcio F; Fusco A; Melillo RM; Santoro M
    Oncogene; 2004 Mar; 23(12):2188-96. PubMed ID: 14981541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
    Zhou D; Li Z; Bai X
    Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells.
    Wang C; Mayer JA; Mazumdar A; Brown PH
    Breast Cancer Res Treat; 2012 Jun; 133(2):487-500. PubMed ID: 21947652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cells.
    De Falco V; Tamburrino A; Ventre S; Castellone MD; Malek M; Manié SN; Santoro M
    Cancer Res; 2012 Mar; 72(6):1449-58. PubMed ID: 22271686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma.
    Gujral TS; van Veelen W; Richardson DS; Myers SM; Meens JA; Acton DS; Duñach M; Elliott BE; Höppener JW; Mulligan LM
    Cancer Res; 2008 Mar; 68(5):1338-46. PubMed ID: 18316596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.